Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 8/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502811 | 0.86 | MEN1 (0.47) | ACHEMEN1KMT2APKMBCHE | |
| SCHEMBL5508099 | 0.85 | MEN1 (0.47) | ACHEMEN1KMT2APKMTOP2A | |
| SCHEMBL5506961 | 0.80 | MEN1 (0.49) | ACHEMEN1KMT2APKMBCHE | |
| SCHEMBL5510251 | 0.77 | TOP2A (0.48) | ACHEMEN1KMT2APKMTOP2A | |
| SCHEMBL5503230 | 0.75 | HPGDS (0.41) | ACHEMEN1KMT2APKM | |
| SCHEMBL5501700 | 0.72 | TOP2A (0.46) | MEN1KMT2APKMTOP2A | |
| SCHEMBL3864066 | 0.72 | ACHE (0.49) | ACHEBCHE | |
| SCHEMBL2052464 | 0.71 | MEN1 (0.57) | MEN1KMT2APKMTOP2A | |
| SCHEMBL1950078 | 0.71 | POLB (0.46) | ACHEMEN1KMT2APKMBCHE | |
| SCHEMBL15867118 | 0.71 | POLB (0.67) | ACHEMEN1KMT2ABCHETOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753724-A1 | HETEROCYCLIC DERIVATIVES FOR TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060009487-A1 | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | SIRCAR JAGADISH C | 2006-01-12 | — | — | US | disclosed |
| WO-2005123686-A1 | HETEROCYCLIC DERIVATIVES FOR TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009487-A1 | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | LDLR, NPC1L1, CETP | ACHE 3585/4885PPARG 148/4885MEN1 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.